AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2019 Financial Results on May 8, 2019

April 1, 2019

CLEARWATER, Fla.--(BUSINESS WIRE)--Apr 1, 2019--Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma ®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced that financial results for the first quarter of fiscal year 2019 will be released after the market closes on Wednesday, May 8.

Management will host a conference call at 4:30 p.m. Eastern Time on May 8 to discuss the results of the quarter and to host a question and answer session. To listen to the call by phone, interested parties may dial 844-507-6493 (or 647-253-8641 for international callers) and provide access code 8252538. Participants should ask for the Apyx Medical Corporation Call. A live webcast of the call will be accessible via the Investor Relations section of the Company’s website and at: https://event.on24.com/wcc/r/1960685/EA5CE433FA4C050FACEFFFC1DF623FB1.

A telephonic replay will be available approximately two hours after the end of the call through May 22, 2019. The replay can be accessed by dialing 800-585-8367 for U.S. callers or 416-621-4642 for international callers and using the replay access code: 8252538. The webcast will be archived on the Investor Relations section of the Company’s website.

About Apyx Medical Corporation :

Apyx Medical Corporation (formerly Bovie Medical Corporation) is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company’s Helium Plasma Technology is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma ® in the hospital surgical market. Renuvion offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190401005033/en/

CONTACT: Investor Relations Contact:

Westwicke Partners on behalf of Apyx Medical Corporation

Mike Piccinino, CFA

investor.relations@apyxmedical.com

KEYWORD: UNITED STATES NORTH AMERICA FLORIDA NEW YORK

INDUSTRY KEYWORD: SURGERY HEALTH HOSPITALS PROFESSIONAL SERVICES FINANCE MEDICAL SUPPLIES GENERAL HEALTH

SOURCE: Apyx Medical Corporation

Copyright Business Wire 2019.

PUB: 04/01/2019 07:30 AM/DISC: 04/01/2019 07:30 AM

http://www.businesswire.com/news/home/20190401005033/en